| 货号 | 54240S |
| 同种亚型 | Rabbit IgG |
| 反应种属 | H M R Mk |
| 来源宿主 | Rabbit IgG |
| 应用 | IP |
| 目标/特异性 | Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (A4M8T) Rabbit mAb (Sepharose® Bead Conjugate) detects endogenous levels of p44 and p42 MAP Kinase (Erk1 and Erk2) when phosphorylated either individually or dually at Thr202 and Tyr204 of Erk1 (Thr185 and Tyr187 of Erk2). The antibody does not cross-react with the corresponding phosphorylated residues of either JNK/SAPK or p38 MAP Kinase, and does not cross-react with non-phosphorylated Erk1/2. |
| 使用方法 | IP(1:20) |
| 供应商 | CST |
| 灵敏度 | Endogenous |
| 背景 | Mitogen-activated protein kinases (MAPKs) are a widely conserved family of serine/threonine protein kinases involved in many cellular programs, such as cell proliferation, differentiation, motility, and death. The p44/42 MAPK (Erk1/2) signaling pathway can be activated in response to a diverse range of extracellular stimuli including mitogens, growth factors, and cytokines (1-3), and research investigators consider it an important target in the diagnosis and treatment of cancer (4). Upon stimulation, a sequential three-part protein kinase cascade is initiated, consisting of a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). Multiple p44/42 MAP3Ks have been identified, including members of the Raf family, as well as Mos and Tpl2/COT. MEK1 and MEK2 are the primary MAPKKs in this pathway (5,6). MEK1 and MEK2 activate p44 and p42 through phosphorylation of activation loop residues Thr202/Tyr204 and Thr185/Tyr187, respectively. Several downstream targets of p44/42 have been identified, including p90RSK (7) and the transcription factor Elk-1 (8,9). p44/42 are negatively regulated by a family of dual-specificity (Thr/Tyr) MAPK phosphatases, known as DUSPs or MKPs (10), along with MEK inhibitors, such as U0126 and PD98059. |
| 运输条件 | 0.75 |
| 存放说明 | -20C |
| 计算分子量 | 42, 44 |
| 参考文献 | 1 . Roux, P.P. and Blenis, J. (2004) Microbiol Mol Biol Rev 68, 320-44. 2 . Baccarini, M. (2005) FEBS Lett 579, 3271-7. 3 . Meloche, S. and Pouysségur, J. (2007) Oncogene 26, 3227-39. 4 . Roberts, P.J. and Der, C.J. (2007) Oncogene 26, 3291-310. 5 . Rubinfeld, H. and Seger, R. (2005) Mol Biotechnol 31, 151-74. 6 . Murphy, L.O. and Blenis, J. (2006) Trends Biochem Sci 31, 268-75. 7 . Dalby, K.N. et al. (1998) J Biol Chem 273, 1496-505. 8 . Marais, R. et al. (1993) Cell 73, 381-93. 9 . Kortenjann, M. et al. (1994) Mol Cell Biol 14, 4815-24. 10 . Owens, D.M. and Keyse, S.M. (2007) Oncogene 26, 3203-13. |
Immunoprecipitation of extracts from HeLa cells, treated with either U0126 #9903 (10uM, 1 hour, lanes 1, 3, and 5) or TPA #4147 (200uM 20 minutes, lanes 2, 4, and 6) using #3423 Rabbit (DA1E) mAb IgG XP® Isotype Control (Sepharose® Bead Conjugate) (lanes 1 and 2) or Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D6A9) Rabbit mAb (Sepharose® Bead Conjugate) (lanes 3 and 4). Lanes 5 and 6 are 10% input. Western blot analysis performed using #8544 Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (HRP Conjugate). |
